Jiya Acquisition Corp.
We intend to initially focus our search on identifying a prospective target business in the biotechnology and pharmaceuticals sector. The company is sponsored by Jiya Holding Co. LLC, an affiliate of Samsara BioCapital, L.P.
In addition, we believe our ability to complete our initial business combination will be enhanced by our having entered into the forward purchase agreement pursuant to which Samsara BioCapital agreed to purchase an aggregate of up to 2,500,000 forward purchase shares, at an aggregate purchase price of up to $25,000,000, in a private placement to close substantially concurrently with the closing of our initial business combination.
Samsara BioCapital, which commenced operations on March 22, 2017, is a registered investment advisor that was organized for the purpose of providing a limited number of select investors with the opportunity to realize long-term capital appreciation from investments in assets and securities of all kinds, including debt securities, in public and private companies in life science-related industries. As of Sept. 1, 2020, the partnership had $671 million in regulatory assets under management.
Samsara BioCapital founder Srini Akkaraju, M.D., Ph.D., is our chairman. Rekha Hemrajani is our CEO. She is an experienced biopharma executive with extensive senior management experience in both large and small publicly traded biopharmaceutical companies.
(Note: This is a blank-check IPO of shares of common stock. Most blank-check or SPAC IPOs are unit offerings.)
|Address||628 Middlefield Road Palo Alto, CA 94301|
|Phone Number||(650) 285-4270|
|View Prospectus:||Jiya Acquisition Corp.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$0 mil (last 12 months)|
|Price range||$10.00 - $10.00|
|Est. $ Volume||$100.0 mil|
|Manager / Joint Managers||Citigroup|
|Expected To Trade:||11/19/2020|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|